Carregando...
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activit...
Na minha lista:
Publicado no: | Antimicrob Agents Chemother |
---|---|
Principais autores: | , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society for Microbiology
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4775926/ https://ncbi.nlm.nih.gov/pubmed/26824950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02524-15 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|